Eli Lilly's new program aims to boost employer coverage of GLP-1s
Shelby Livingston / endpoints - With insurance coverage of weight loss medications stalled, Eli Lilly has developed a program to give employers another way to pay for their workers' GLP-1 treatments. The pharma giant on Thursday announced the launch of ...
AI Summary: Eli Lilly unveiled an Employer Connect program designed to help employers expand coverage for GLP‑1–class weight‑loss drugs amid stalled insurer uptake. The initiative offers new contracting and access pathways for workplaces, addressing demand while prompting debate over whether it changes the underlying benefit‑design economics. It’s helpful—if you don’t expect a revolution.
Patients with multiple chronic diseases are a looming threat to health systems' financials: Vizient
fiercehealthcare - A recent claims data analysis shows the 11% of people with multiple chronic conditions are behind 52% of inpatient admissions and about a third of outpatient visits. Their projected increases and unfavorable payer mix spell trouble for health systems' bot…
AI Summary: A Vizient analysis shows roughly 11% of the U.S. population accounts for about 52% of hospital admissions, spotlighting how patients with multiple chronic conditions consume disproportionate inpatient resources. The report warns this concentration strains hospital finances and operational capacity, and calls for targeted care models to manage high‑need populations more efficiently.
Elizabeth McKenna: New Cancer Grand Challenges Teams Announced
oncodaily - Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: “The new Cancer Grand Challenges teams have just been announced! Read about the teams tackling cancer avoidance, mechanisms […]
AI Summary: Global funders announced new Cancer Grand Challenges awards, backing five international teams with large, high‑risk grants to pursue transformative cancer science. The initiative aims to accelerate unconventional, high‑reward projects and foster cross‑disciplinary collaboration — essentially underwriting audacity in hopes that at least one risky bet pays off.
CART19-BE-02 trial: From Bench to Bedside and Beyond – Resonance
oncodaily - ALRCaN presents “CART19-BE-02 trial: From Bench to Bedside and Beyond—Implementing a Hospital-Based CAR T Program and Integrating It into the Spanish NHS” with Dr. Valentín Ortiz-Maldonado. “Dear friends and colleagues, […]
AI Summary: Bereaved relatives delivered searing final testimonies as the Covid inquiry wound up four years of public hearings, recounting loved ones who died alone and demanding answers. Chair Baroness Heather Hallett defended the process and its roughly £200 million price tag as necessary to finish the work, despite public frustration and political scrutiny.
Telehealth growth hasn’t increased rural behavioral healthcare access: Study
Giles Bruce / beckershospitalreview - The rise in telemedicine over the past several years hasn’t translated to more behavioral healthcare access in rural areas, according to a March 5 study in JAMA Network Open. Researchers from Boston-based Harvard Medical School and Providence, R.I.-based …
AI Summary: A new study finds the rapid expansion of telemedicine did not meaningfully improve access to behavioral health services in rural areas. Persistent barriers—workforce shortages, broadband gaps, and reimbursement limits—keep telehealth from being the miracle fix some hoped for. Turns out, high-speed internet isn’t a therapist.
New FDA bonus pilot to address 'workforce challenges'
Max Bayer / endpoints - A new bonus pilot program meant to reward fast-working FDA reviewers will be funded in part by money from industry user fees, the first details on how Commissioner Marty Makary plans to finance the incentive ...
AI Summary: The FDA has introduced a pilot program offering performance bonuses to expedite regulatory reviews, aiming to tackle reviewer workload and improve timeliness. Funded partly by industry user fees, the initiative seeks to reward faster, high‑quality reviews while balancing independence and efficiency—proof that carrots sometimes replace the endless stick of overtime.
Optum Rx, Caremark making ‘significant progress’ in settlement talks with FTC
Rebecca Pifer Parduhn / healthcaredive - It’s looking increasingly likely that the UnitedHealth and CVS drug middlemen will also make peace with federal regulators, after Cigna agreed to a sweeping settlement in the insulin lawsuit last month.
AI Summary: Federal regulators and two pharmacy benefit managers are reportedly making substantial progress toward resolving an FTC antitrust probe tied to insulin pricing and PBM practices. Negotiations aim to settle allegations without protracted litigation, potentially changing how PBMs operate and how insulin costs are managed for states and patients.
Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology
Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…
AI Summary: Moderna has agreed to settle long-running patent disputes over its COVID-19 vaccine technology for up to $2.25 billion, resolving litigation with several claimants. The deal provides Moderna with broad licensing rights and clears a major legal uncertainty, allowing the company to move forward without another courtroom cliffhanger.
Servier Boosts Presence in Rare Cancers With $2.5B Acquisition of Day One Biopharma
Frank Vinluan / medcitynews - Day One Biopharmaceuticals is Servier’s biggest acquisition yet, topping the $2.4 billion it paid to buy Shire’s cancer business in 2018. Day One markets Ojemda, approved for treating pediatric low-grade glioma, the most common type of brain cancer in chi…
AI Summary: Servier is buying Day One Biopharmaceuticals for about $2.5 billion to bolster its rare oncology portfolio, gaining access to promising targeted therapies. The deal expands Servier’s presence in specialty cancer medicines and aligns with its strategic push into rare tumors, with integration and regulatory steps expected to follow.